

产品名称: **SGX-523**

产品别名: **SGX-523**

生物活性:						
Description		SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC50 value: 4 nM [1] Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors. SGX-523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for its selectivity. SGX523 potently inhibits the purified MET catalytic domain but not the closely related receptor tyrosine kinase RON. SGX523 indicates ATP-competitive inhibition with higher apparent affinity for the less active, unphosphorylated form of MET [MET-KD(OP), with a Ki of 2.7 nM] versus the more active phospho-enzyme [MET-KD(3P), with a Ki of 23 nM], a phenomenon consistent with preferential binding to an inactive enzyme conformation. SGX523 inhibits MET-mediated signaling, cell proliferation and cell migration at nanomolar concentrations but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concentrations [1]. in vivo: SGX523 significantly retards the growth of preestablished GTL16 tumors when administered orally at doses of ≥ 10 mg/kg twice daily. SGX523 potently inhibits U87MG tumor growth; at 30 mg/kg dosed twice daily, SGX523 leads to clear regression of U87MG tumors. SGX523, dosed twice daily at 30 mg/kg, also retards the growth of H441 tumors with concomitant reduction in tumor MET autophosphorylation levels. SGX523 inhibition of MET in vivo is associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma, lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity [1].				
Solvent&Solubility		In Vitro: DMSO : ≥ 3.6 mg/mL (10.02 mM) * "≥" means soluble, but saturation unknown.				
			<div>SolventMassConcentration</div>	1 mg	5 mg	10 mg
		Preparing	1 mM	2.7823 mL	13.9117 mL	27.8234 mL
		Stock Solutions	5 mM	0.5565 mL	2.7823 mL	5.5647 mL
			10 mM	0.2782 mL	1.3912 mL	2.7823 mL
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时，请在 6 个月内使用， -20°C 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>1.SGX-523 is prepared in 0.5% sodium carboxymethyl cellulose[2].</p>						
References		<p>[1]. Buchanan SG, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009, 8(12), 3181-3190.</p> <p>[2]. Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59.</p>				